癌症和树皮细胞之间的代谢交叉:对精密瘤学的影响
Wanwan Yang1, Yuwen Ding2, Hongzhan Tian3
1Fuyang Hospital Affiliated to Anhui Medical University, Fuyang, China.
Surgical oncology
|February 17, 2026
概括
癌细胞在瘤微环境 (TME) 中通过与树皮细胞的交叉声调重新编程新陈代谢. 针对这种代谢共生提供了针对癌症生长和耐药性的新的精确瘤学策略.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 代谢过程中的代谢.
背景情况:
- 代谢重编程是癌症的一个关键标志.
- 瘤细胞通过代谢交叉交互与瘤微环境 (TME) 相互作用.
- 这种相互作用涉及纤维细胞,免疫细胞,内皮细胞和脂肪细胞.
研究的目的:
- 探索TME内部复杂的代谢网络.
- 了解癌细胞和树皮组成部分之间的动态代谢交叉声.
- 通过了解瘤-肌体代谢合作来确定新的治疗点.
主要方法:
- 对指导代谢对话的信号通路 (HIF-1α,mTOR,AMPK,c-Myc,PPAR,NRF2) 的审查.
- 对将代谢流与基因表达联系起来的表观遗传机制的分析.
- 应用新兴技术,如空间代谢学和单细胞多组学.
主要成果:
- 癌细胞和树皮细胞交换代谢物,影响能量生产,氧化还原稳定和生物合成.
- 与癌症相关的纤维细胞 (CAF) 提供乳酸和脂质;免疫细胞面临代谢抑制;内皮细胞和脂肪细胞支持血管生成.
- 关键的信号通路和表观遗传修饰调节了这种代谢通信.
结论:
- 在TME内的代谢共生对于瘤生长,免疫逃避和治疗耐药性至关重要.
- 针对代谢共生,而不是孤立的途径,是精确瘤学的有希望的战略.
- 了解患者特定的代谢依赖性可以个性化基于代谢的癌症干预措施.
相关概念视频
The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Cancer Stem Cells and Tumor Maintenance
6.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Metastasis
6.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.7K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K


